Arclio

Arclio is a clinical-evidence platform for biopharma. It gives regulatory, clinical, and biostatistics teams FDA-defensible answers from their trial data in 30 seconds, not three days. Unlike tools that only show where a number came from, Arclio proves it correct and unaltered through deterministic, re-runnable computations on a tamper-evident evidence chain. The agent runs entirely inside your own infrastructure — no data ever moves. It produces publication-grade charts and an FDA readiness sco[1][2]

Visit website Suggest an update

2025 Founded2 People on the graph

Overview

Arclio is a clinical-evidence platform for biopharma [2]. The company provides regulatory, clinical, and biostatistics teams with FDA-defensible answers from trial data in 30 seconds, rather than three days [2]. Arclio's approach differs from other tools by proving the correctness and integrity of data through deterministic, re-runnable computations on a tamper-evident evidence chain [2]. The platform operates entirely within client infrastructure, ensuring that no data moves externally [2]. Arclio produces publication-grade charts and an FDA readiness score [2]. The company is listed in the Apollo NYC AI directory under the devtools category [1] and operates in the technology, information and internet industry [3].

Growth & traction

LinkedIn lists 3 people working at Arclio. [4]

Leadership & org chart

Jacques KotzeFounder

Something wrong or missing? Send an update. Fixed within 24 hours.